Evidence map›Paper›PMID 40520449›Full record

ArticleJournal of the Endocrine Society2025

Changes After Leptin Administration in Partial Lipodystrophy and Factors Associated With Hepatic and Metabolic Response.

Baris Akinci, Nevin Ajluni, Rasimcan Meral, Adam Hugh Neidert, Maria Foss Freitas, Donatella Gilio, Hari Conjeevaram, Elif Arioglu Oral

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01679197 (Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01679197 phase2completednot on this map

Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

TypeinterventionalSponsorUniversity of MichiganRan2012 to 2016Enrolled23ConditionsFatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, LipodystrophyArmsMetreleptin
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Baris AkinciCaswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Nevin AjluniCaswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Rasimcan MeralCaswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Adam Hugh NeidertCaswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Maria Foss FreitasCaswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Donatella GilioCaswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.
Hari ConjeevaramDivision of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Elif Arioglu OralCaswell Diabetes Institute and Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI 48109, USA.ORCID https://orcid.org/0000-0002-9171-1144

Funding

Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
University of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILEY, JOHN W · 1986 to 2021
$22.5M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Joyce Lee · 2010 to 2026
$20.3M
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)R01DK088114 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CONJEEVARAM, HARI S, ORAL, ELIF ARIOGLU · 2011 to 2015
$1.7M
NCATS NIH HHS UL1 TR000433NIDDK NIH HHS P30 DK034933NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R01 DK088114
6 · The paper itself

Abstract

Context: Partial lipodystrophy (PL) is a rare disease characterized by selective loss of subcutaneous fat. Objective: To evaluate changes in apolipoproteins, hepatokines, hormones, appetite regulators, and inflammatory markers in patients with PL treated with leptin, assess postprandial metabolism and 24-hour dynamics, and identify predictors of hepatic and metabolic response to therapy. Methods: We studied 19 subjects from our previous clinical study (NCT01679197), which investigated the effect of leptin on metabolic dysfunction-associated steatohepatitis associated with PL. A mixed-meal test was performed in a subgroup of 14 patients, and paired 24-hour frequent sampling with standardized meals was completed in 5 individuals. Results: Leptin treatment led to reductions in apolipoproteins B, CII, CIII, and E ( Conclusion: Leptin therapy modulates lipid metabolism, postprandial glucose regulation, and appetite signaling in patients with PL, with responses associated with metabolic parameters and carbohydrate intake.

Indexed as

incretinsleptinMASHpartial lipodystrophyresponse

Identifiers

PMID40520449
PMCPMC12164294

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.